Sign In
Buy ALEC
$1.78
-0.175 (-8.97%)
At Close: Jun 03, 2026
Alector (ALEC) Reports Q2 Loss, Misses Revenue Estimates
09:55pm, Tuesday, 11'th Aug 2020
Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Alector Reports Second Quarter 2020 Financial Results and Provides Corporate Update
08:05pm, Tuesday, 11'th Aug 2020
* Pivotal Phase 3 trial of AL001 initiated for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) * Promising preliminary data from AL001 Phase 1b and Phase 2 open-
SG Americas Securities LLC Has $334,000 Stock Holdings in Alector Inc (NASDAQ:ALEC)
10:32am, Tuesday, 11'th Aug 2020
SG Americas Securities LLC grew its stake in Alector Inc (NASDAQ:ALEC) by 35.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The insti
Orchard Therapeutics plc (ORTX) CEO Bobby Gaspar on Q2 2020 Results - Earnings Call Transcript
07:32pm, Saturday, 08'th Aug 2020
Orchard Therapeutics plc (NASDAQ:ORTX) Q2 2020 Results Conference Call August 06, 2020 08:00 AM ET Company Participants Renee Leck - Investor Relations Bobby Gaspar - Chief Executive Officer Frank Tho
Alector Looks Like A Buy After Huge Selloff (NASDAQ:ALEC)
12:30pm, Friday, 07'th Aug 2020
Alector released preliminary data from its ongoing Phase 2 trial of AL001 in frontotemporal dementia on July 28.
Alector to Present at the BTIG Virtual Biotechnology Conference 2020
12:30pm, Tuesday, 04'th Aug 2020
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D.
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
04:31pm, Monday, 03'rd Aug 2020
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Alector Is Tumbling 28.7% Today
05:00pm, Wednesday, 29'th Jul 2020
Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
11:32am, Wednesday, 29'th Jul 2020
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Fulgent Genetics Inc (NASDAQ: FLGT
Alector (ALEC) Presents At Alzheimer's Association International Conference: AICC 2020 - Slideshow
07:27am, Wednesday, 29'th Jul 2020
The following slide deck was published by Alector, Inc. in conjunction with this event..
* AL001 was generally safe and well-tolerated in Phase 1b study and after continuous dosing in 15 asymptomatic and symptomatic FTD-GRN participants in Phase 2 study * Treatment with AL001 in Phas
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
Stocks To Watch: Big Focus On Big Tech
08:26am, Saturday, 25'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
13Ds Filings
10:12pm, Friday, 24'th Jul 2020
Activist reports to the SEC from July 16 through July 22, 2020, including positions in Anterix, Inventiva, BeiGene, and two other companies
Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia
12:30pm, Friday, 24'th Jul 2020
* Trial will enroll up to 180 symptomatic and pre-symptomatic participants with FTD-GRN gene mutation at multiple sites in the U.S., Europe and Australia * There are currently no FDA-approved treatm
